196 related articles for article (PubMed ID: 19697155)
21. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.
Punnen S; Cowan JE; Chan JM; Carroll PR; Cooperberg MR
Eur Urol; 2015 Oct; 68(4):600-8. PubMed ID: 25242555
[TBL] [Abstract][Full Text] [Related]
22. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer.
Lubeck DP; Grossfeld GD; Carroll PR
Urology; 2001 Aug; 58(2 Suppl 1):94-100. PubMed ID: 11502459
[TBL] [Abstract][Full Text] [Related]
23. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
24. The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE).
Anast JW; Sadetsky N; Pasta DJ; Bassett WW; Latini D; DuChane J; Chan JM; Cooperberg MR; Carroll PR; Kane CJ
J Urol; 2005 Apr; 173(4):1132-8. PubMed ID: 15758721
[TBL] [Abstract][Full Text] [Related]
25. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.
Cooperberg MR; Broering JM; Litwin MS; Lubeck DP; Mehta SS; Henning JM; Carroll PR;
J Urol; 2004 Apr; 171(4):1393-401. PubMed ID: 15017184
[TBL] [Abstract][Full Text] [Related]
26. A prospective analysis of health-related quality of life in intermediate and high-risk prostate cancer patients managed with intensity modulated radiation therapy, with vs. without hormonal therapy.
Caumont F; Conti G; Hurwitz LM; Kuo C; Levie KE; Badiozamani K; Frankel JK; Flores JP; Brand TC; Chaurasia A; Rosner IL; Stroup SP; Musser JE; Cullen J; Porter CR
Urol Oncol; 2020 Oct; 38(10):794.e1-794.e9. PubMed ID: 32139288
[TBL] [Abstract][Full Text] [Related]
27. A prospective study of health-related quality of life outcomes among men treated for intermediate- and high-risk prostate cancer: the impact of primary and secondary therapies.
Alsinnawi M; Cullen J; Hurwitz LM; Levie KE; Burns JF; Rosner IL; Brand TC; Stroup S; Sterbis JR; Rice K; Conti G; Porter CR
Can J Urol; 2019 Aug; 26(4):9809-9820. PubMed ID: 31469635
[TBL] [Abstract][Full Text] [Related]
28. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
Mitchell JA; Cooperberg MR; Elkin EP; Lubeck DP; Mehta SS; Kane CJ; Carroll PR
J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720
[TBL] [Abstract][Full Text] [Related]
29. The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer.
Penson DF; Stoddard ML; Pasta DJ; Lubeck DP; Flanders SC; Litwin MS
J Clin Epidemiol; 2001 Apr; 54(4):350-8. PubMed ID: 11297885
[TBL] [Abstract][Full Text] [Related]
30. Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study.
Sureda A; Fumadó L; Ferrer M; Garín O; Bonet X; Castells M; Mir MC; Abascal JM; Vigués F; Cecchini L; Suárez JF
Health Qual Life Outcomes; 2019 Jan; 17(1):11. PubMed ID: 30642340
[TBL] [Abstract][Full Text] [Related]
31. Comparison of oncological and health-related quality of life outcomes between open and robot-assisted radical prostatectomy for localised prostate cancer - findings from the population-based Victorian Prostate Cancer Registry.
Ong WL; Evans SM; Spelman T; Kearns PA; Murphy DG; Millar JL
BJU Int; 2016 Oct; 118(4):563-9. PubMed ID: 26573954
[TBL] [Abstract][Full Text] [Related]
32. The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry.
Husson O; de Rooij BH; Kieffer J; Oerlemans S; Mols F; Aaronson NK; van der Graaf WTA; van de Poll-Franse LV
Oncologist; 2020 Apr; 25(4):e722-e732. PubMed ID: 32297435
[TBL] [Abstract][Full Text] [Related]
33. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
D'Amico AV; Moul JW; Carroll PR; Sun L; Lubeck D; Chen MH
J Natl Cancer Inst; 2003 Sep; 95(18):1376-83. PubMed ID: 13130113
[TBL] [Abstract][Full Text] [Related]
34. Deterioration in Health-Related Quality of Life Diminishes Benefit of Lung Cancer Resection in Older Adults.
Blakely AM; Hu H; Wong FL; Raz DJ; Erhunmwunsee L; Sun V; Kim JY
Clin Lung Cancer; 2021 Jul; 22(4):e544-e551. PubMed ID: 32727705
[TBL] [Abstract][Full Text] [Related]
35. Severity of cardiovascular disease and health-related quality of life in men with prostate cancer: a longitudinal analysis from CaPSURE.
van de Poll-Franse LV; Sadetsky N; Kwan L; Litwin MS
Qual Life Res; 2008 Aug; 17(6):845-55. PubMed ID: 18506598
[TBL] [Abstract][Full Text] [Related]
36. Quality of life measures (EORTC QLQ-C30 and SF-36) as predictors of survival in palliative colorectal and lung cancer patients.
Grande GE; Farquhar MC; Barclay SI; Todd CJ
Palliat Support Care; 2009 Sep; 7(3):289-97. PubMed ID: 19788770
[TBL] [Abstract][Full Text] [Related]
37. Identification and prediction of health-related quality of life trajectories after a prostate cancer diagnosis.
Farris MS; Kopciuk KA; Courneya KS; McGregor SE; Wang Q; Friedenreich CM
Int J Cancer; 2017 Apr; 140(7):1517-1527. PubMed ID: 28006843
[TBL] [Abstract][Full Text] [Related]
38. The impact of obesity on overall and cancer specific survival in men with prostate cancer.
Davies BJ; Smaldone MC; Sadetsky N; Dall'era M; Carroll PR
J Urol; 2009 Jul; 182(1):112-7; discussion 117. PubMed ID: 19447437
[TBL] [Abstract][Full Text] [Related]
39. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
40. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
